• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for...

cafead

Administrator
Staff member
  • cafead   Sep 12, 2022 at 11:22: AM
via Bristol Myers Squibb's and Roche's immunotherapies have both failed to move the needle when used after surgery in early-stage kidney cancer. But the two companies’ setbacks aren’t necessarily a full relief for Merck’s rival drug Keytruda.

article source
 

<